Spironolactone does not reduce the rate of cardiovascular death or heart failure in patients undergoing maintenance dialysis.

ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical ...

Investigators successfully tested an acellular tissue engineered vessel for hemodialysis vascular access in patients at high-risk for arteriovenous fistula (AVF) maturation failure.

Artificial intelligence and telemedicine are transforming dialysis care, improving predictions, expanding access, and enabling patient-centered home therapies.

Dual eligibility was a proxy for high social risk in a retrospective study that compared outcomes in that group with ...

AV Access Study to be Presented at the Vascular Annual Meeting (VAM25)DURHAM, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company ...

Akebia continues to publish important, clinically relevant data to further physicians’ understanding of Vafseo® (vadadustat)CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, ...

Steroidal mineralocorticoid receptor antagonists (MRAs) may not lower risk for all-cause or cardiovascular (CV) mortality among patients receiving maintenance dialysis, according to a meta-analysis ...

Researchers at Yale School of Medicine have determined that a panel of biomarkers can help physicians better understand ...

An investigational anticoagulant that targets factor XI failed to prevent arteriovenous graft (AVG) thrombosis in chronic ...